« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5
, Pages
1193-1200
, November 2007
Defective T-cell activation caused by impairment of the TNF receptor 2 costimulatory pathway in common variable immunodeficiency
-
Defective TCR stimulation in patients with CVID is not corrected if T cells are preactivated. T cells were precultured with or without anti-CD3 mAb for 10 to 17 days and restimulated with anti-TCR/ant
Defective TCR stimulation in patients with CVID is not corrected if T cells are preactivated. T cells were precultured with or without anti-CD3 mAb for 10 to 17 days and restimulated with anti-TCR/anti-CD28 mAbs for 5 days. IFN-γ release was determined by ELISA (A; bars = median). At the end of preculture, the percentage of CD4 and CD8 positive cells was determined by flow cytometry (B). Co, Controls.
-
Calcium influx through SOC channels is normal in patients with CVID. PBMCs were loaded, stained for CD4, and resuspended in calcium-free medium. Baseline calcium concentration was established in the pCalcium influx through SOC channels is normal in patients with CVID. PBMCs were loaded, stained for CD4, and resuspended in calcium-free medium. Baseline calcium concentration was established in the presence of ethyleneglycol-bis(β-aminoethylether)-N,N,N′-N′-tetraacetic acid (EGTA). Thapsigargin was added to deplete intracellular calcium stores. After a further 10 minutes, calcium was added, and the increase in intracellular calcium represents influx through SOC channels. MFI, Mean fluorescence intensity.
-
Translocation of PKC-θ is normal in patients with CVID. PBMCs were stimulated for 15 minutes (PMA 10 ng/mL), lysed, and separated into a membrane and cytosolic fraction. PKC-θ, PKC-βI (loading controlTranslocation of PKC-θ is normal in patients with CVID. PBMCs were stimulated for 15 minutes (PMA 10 ng/mL), lysed, and separated into a membrane and cytosolic fraction. PKC-θ, PKC-βI (loading control), and fyn (membrane control) were examined by Western blot. (A) One representative experiment, (B) individual results for membrane extracts, and (C) densitometric readings (means ± SEMs) of membrane extracts. med., Cells treated with culture medium alone.
-
TCR costimulation via TNF-RII is defective in patients with CVID. Precultured (A; means ± SEMs; n = 8) or freshly isolated nonadherent lymphocytes (B; 1 experiment of 3) were stimulated with anti-TCRTCR costimulation via TNF-RII is defective in patients with CVID. Precultured (A; means ± SEMs; n = 8) or freshly isolated nonadherent lymphocytes (B; 1 experiment of 3) were stimulated with anti-TCR ± TNF-α or TNF-RII mAbs. C, Means ± SEMs, ● = XLA patient 3, ▴= XLA patient 5, ▪ = IgG subclass deficiency, ♦ = IgM deficiency. dpm, Disintegrations per minute.
-
TCR/CD28-induced proliferation and IL-2 secretion but not TCR/CD28-induced TRAF1 expression requires concomitant TNF-RII triggering. T cells were stimulated with anti-TCR/CD28 mAbs in the presence orTCR/CD28-induced proliferation and IL-2 secretion but not TCR/CD28-induced TRAF1 expression requires concomitant TNF-RII triggering. T cells were stimulated with anti-TCR/CD28 mAbs in the presence or absence of anti–TNF-α or an isotype control mAb (1 ug/mL). Bars represent the means ± SEMs of 4 (A) or 3 (B; IL-2 release determined by ELISA) experiments. C, TRAF1: 1 representative Western blot experiment of 4. med., Cells treated with culture medium alone; dpm, disintegrations per minute.
-
TCR and TCR/CD28-induced TRAF1 expression is normal in patients, but TCR/TNF-RII–induced TRAF1 expression is impaired. T cells were stimulated for 3 days (isotype control mAb coated beads = cobeads) aTCR and TCR/CD28-induced TRAF1 expression is normal in patients, but TCR/TNF-RII–induced TRAF1 expression is impaired. T cells were stimulated for 3 days (isotype control mAb coated beads = cobeads) and Western blots for TRAF1 (B) and TRAF2 were performed. The densitometric readings for TRAF1 are given in A (means ± SEMs; insert = densitometry for TRAF2). A ratio for TRAF1 densitometry was calculated in C. lono, Lonomycin; Co, controls.
Supported by Österreichische Nationalbank, Jubiläumsfond, grant number 7850.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
PII: S0091-6749(07)01354-1
doi: 10.1016/j.jaci.2007.07.004
© 2007 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5
, Pages
1193-1200
, November 2007
